Drug Development in the New Era:
A Global Perspective
Drug Development in the New Era:
A Global Perspective
Opportunity to meet and interact with globally renowned speakers and experts.
Exchanging ideas on the latest trends on new drug development in various disease areas, in Asia and worldwide.
ICPOEP2018 is a truly global event in clinical research, bringing together professionals from academic institutions, healthcare organizations, pharmaceutical companies, CROs regulatory authorities and others in exchanging insight and wisdom on the latest trends on new drug development. This year, the highlights will be clinical pharmacology, neurology and oncology.
SUPPORT FROM NEW β INNOVATION FOR THE ORGANIZATION OF THIS CONFERENCE IS GRATEFULLY ACKNOWLEDGED
The University of Hong Kong Clinical Trials Centre (HKU-CTC) is celebrating its 20th anniversary!
HKU-CTC is an academic clinical research organization established under The University of Hong Kong (HKU) in 1998. It has been authorized as the central platform for management and coordination of clinical studies under HKU and its affiliated teaching hospital – Queen Mary Hospital.
Over the years, HKU-CTC has developed into a leading, full-service professional research organization offering one-stop clinical research solutions. HKU-CTC is devoted to partnering with clinical investigators, research organizations and the healthcare industry in advancing human healthcare by promoting, attracting and facilitating clinical studies of various natures, including:
Learn more about HKU-CTC: www.hkuctc.com
Clinical Trials Centre,
The University of Hong Kong
Clinical Trials Centre,
The University of Hong Kong
Phase 1 Clinical Trials Centre,
The University of Hong Kong
Phase 1 Clinical Trials Centre,
The University of Hong Kong
Phase 1 Clinical Trials Centre,
The University of Hong Kong
Department of Medicine,
The University of Hong Kong
Clinical Trials Centre,
The University of Hong Kong
Phase 1 Clinical Trials Centre,
The University of Hong Kong
Department of Medicine,
The University of Hong Kong
Department of Medicine,
The University of Hong Kong
Department of Medicine,
The University of Hong Kong
Phase 1 Clinical Trials Centre,
The University of Hong Kong
Phase 1 Clinical Trials Centre,
The University of Hong Kong
Department of Medicine,
Queen Mary Hospital
Clinical Trials Centre,
The University of Hong Kong
Distinguished Professor and Chair, Department of Cellular and Molecular Medicine,
University of California San Diego, USA
Faculty of Life Sciences and Medicine,
King’s College London, UK
Director of Stroke, Dementia and Heart Disease Laboratory,
Western University, London, Ontario, Canada
Director of Parkinson's Disease and Movement Disorders Program,
Henry Ford Hospital, Michigan, USA
Managing Director of Neuroscience Institute, Massachusetts General Hospital
Associate Member of Broad Institute, Boston, USA
Syneos Health, Montreal, Canada
Bristol-Myers Squibb, New Jersey, USA
Merck & Co., Inc., USA
Princess Margaret Cancer Centre, Toronto, Canada
Chief Ethics Officer and Vice-Chair of Institutional Review Board,
Jiangsu Province Hospital, Nanjing, China
University of Texas MD Anderson Cancer Center, Houston, USA
Peking University Third Hospital, Beijing, China
Senior Staff Scientist of Ontario Cancer Institute, University Health Network
University Professor of Departments of Medical Biophysics and Immunology, University of Toronto, Toronto, Canada
Janssen Pharmaceutical Companies of Johnson & Johnson, Singapore
Senior Consultant of Division of Surgical Oncology, National Cancer Center Singapore
Senior Consultant of Department of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital, Singapore
China Medical University, Taichung, Taiwan
Clinical Assistant Professor of Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong, HKSAR, China
Department of Medicine, The University of Hong Kong, HKSAR, China
Chair:
Professor Bernard Cheung, Medical Director, Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Professor Shu-Leong Ho, Henry G Leong Professor of Neurology, Department of Medicine, The University of Hong Kong, HKSAR, China
Professor Peter Jenner, Emeritus Professor of Pharmacology, Neurodegenerative Diseases Research Group, Faculty of Life Sciences and Medicine, King’s College London, UK
Professor Peter LeWitt, Professor of Neurology, Wayne State University School of Medicine / Director of Parkinson's Disease and Movement Disorders Program, Henry Ford Hospital, Michigan, USA
Professor Dario Alessi, Director of MRC Protein Phosphorylation & Ubiquitylation Unit, University of Dundee, UK
Chair:
Dr. Koon-Ho Chan, Clinical Associate Professor, Department of Medicine, The University of Hong Kong, HKSAR, China
Dr. Cornelia Man, Director, Clinical Projects and Development, New ß Innovation, HKSAR, China
Dr. Luciano Sposato, Associate Professor of Department of Clinical Neurological Sciences / Director of Stroke, Dementia and Heart Disease Laboratory, Western University, London, Ontario, Canada
Professor Raymond Cheung, Lee Man Chiu Professor in Neuroscience of Division of Neurology, Department of Medicine, The University of Hong Kong, HKSAR, China
Professor Jonathan Rosand, Professor of Neurology, Harvard Medical School / Managing Director of Neuroscience Institute, Massachusetts General Hospital and Associate Member of Broad Institute, Boston, USA
Professor Chung-Yi Hsu, Chair Professor of Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan
Professor Gabriel Leung, GBS, JP, Dean, LKS Faculty of Medicine, The University of Hong Kong, HKSAR, China
Dr. Che-Chung Luk, Cluster Chief Executive, Hong Kong West Cluster, Hospital Authority, HKSAR, China
Chair:
Professor Karen Lam, Chairman, Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Professor Shu-Leong Ho, Henry G Leong Professor of Neurology, Department of Medicine, The University of Hong Kong, HKSAR, China
Professor Don W. Cleveland, Head of Laboratory of Cell Biology, Ludwig Institute for Cancer Research / Distinguished Professor and Chair of Department of Cellular and Molecular Medicine, University of California San Diego, USA
Moderator:
Professor Bernard Cheung, Medical Director, Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Panelist:
Professor Don W. Cleveland, University of California San Diego, USA
Professor Lee M. Ellis, University of Texas MD Anderson Cancer Center, Houston, USA
Dr. Mario Tanguay, Syneos Health, Montreal, Canada
Chair:
Mr. Henry Yau, Managing Director / Honorary Assistant Professor, Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Mr. Daniel Li, Associate Director Clinical Operations Asia Pacific, Gilead Sciences HK Limited, Hong Kong, HKSAR, China
Dr. Mario Tanguay, Vice President of Strategic Development, Syneos Health, Montreal, Canada
Professor Haiyan Li, Professor of Cardiology / Director of Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, China
Ms. Agnes Chan, Specialist, BioResearch Quality & Compliance (BRQC) Quality Management, Janssen Pharmaceutical Companies of Johnson & Johnson, Singapore
Chair:
Dr. Creany Wong, Associate Director, Business & Project Intelligence / Honorary Assistant Professor, Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Dr. Selene Tam, Associate Director, Project Operations, Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Dr. Tommy Cheung, Deputy Medical Director (Clinical Pharmacology) of Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Dr. Xiuqin Wang, Director of Research Operating Office, Jiangsu Academy of Clinical and Translational Research / Chief Ethics Officer and Vice-Chair of Institutional Review Board, Jiangsu Province Hospital, Nanjing, China
Chair:
Professor Ronnie Poon, Medical Director, Hong Kong Integrated Oncology Centre , HKSAR, China
Dr. Roland Leung, Associate Consultant, Department of Medicine, Queen Mary Hospital, HKSAR, China
Professor Tak-wah Mak, Director of the Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre / Senior Staff Scientist of Ontario Cancer Institute, University Health Network / University Professor of Departments of Medical Biophysics and Immunology, University of Toronto, Toronto, Canada
Dr. Archie Tse, Executive Director of Clinical Research Oncology, Merck & Co., Inc., USA
Dr. Jeffrey Jackson, Early Asset Development Lead of Integrated Oncology, Bristol-Myers Squibb, New Jersey, USA
Chair:
Dr. Thomas Yau, Clinical Associate Professor, Department of Medicine, The University of Hong Kong, HKSAR, China
Dr. Joanne Chiu, Deputy Medical Director (Oncology), Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Dr. Carmen Chak-Lui Wong, Assistant Professor of Department of Pathology, The University of Hong Kong, HKSAR, China
Professor Pierce Chow, Professor and Course Director of Duke-NUS Medical School / Senior Consultant of Division of Surgical Oncology, National Cancer Center Singapore / Senior Consultant of Department of Hepatopancreatobiliary / Transplant Surgery, Singapore General Hospital, Singapore
Professor Lillian Siu, Director of Phase I and Cancer Genomics Program / BMO Chair in Precision Genomics, Princess Margaret Cancer Centre, Toronto, Canada
Professor Lee M. Ellis, Professor of Surgery and Molecular & Cellular Biology, University of Texas MD Anderson Cancer Center, Houston, USA
Professor Yu-Lung Lau, Chief Director, Clinical Trials Centre, The University of Hong Kong, HKSAR, China
For enquires, please contact the Conference Secretariat Email: icpoep2018@hku.hk
